Back to top

Image: Bigstock

Mylan N.V.

Read MoreHide Full Article

Mylan received a huge setback when its application for generic Advair was issued a CRL given the potential market for the same. The CRL also puts a question mark on Mylan’s 2017 guidance. Concurrent with the fourth-quarter results earlier in the month, Mylan projected revenues between $12.25 billion and $13.75 billion in 2017. However, with the company’s ANDA for Advair being declined, it might be a daunting task for the company hereafter. Mylan has been under immense pressure since Aug 2016 when the company faced criticism for the price increase of EpiPen since its acquisition of the drug in 2007 from lawmakers, consumers and the common people alike. Nevertheless, fourth-quarter results were boosted by incremental contribution from recent acquisitions. Estimates have been marginally down ahead of the Q1 results. Shares of Mylan have outperformed the industry in the last six months.

Published in